Marketing consultant Buzzback surveyed 800 consumers in March, prior to novel coronavirus shutdowns in the two countries, to identify ingredients that offer opportunities for brands in health care, wellness and skin care.

Firm supplying all-in-one multivitamin blends rather than packs of multiple pills has four-member advisory board including digital marketing and consumer product marketing specialists and a health care strategist.

Series C investment of an undisclosed amount announced in early May follows $20m funding for the Los Angeles company from Volition Capital and angel investors.

When businesses rapidly pivot to offering consumer health products and services, they’re likely not contemplating compliance with FDA regulations. Recent warning letters are more proof COVID-19 represents opportunities for numerous businesses that aren’t prepared to follow or simply aren’t aware of FDA regulations.

Latest warning to Humaworm notes findings that FDA inspectors made in July 2019. FDA officials apparently have been in Humaworm’s facility since then, executing a search warrant in October and confiscating encapsulating machines, herbs, capsules, computers, and records.

“Repeated failures demonstrate that executive management oversight and control over the manufacture of drugs is inadequate,” FDA says. Warning submitted in March said falsifying data was found in making batch release decisions related to whether certain sterile ophthalmic drugs contained viable microorganisms.